These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition. Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381 [TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms. Skowron MA; Vermeulen M; Winkelhausen A; Becker TK; Bremmer F; Petzsch P; Schönberger S; Calaminus G; Köhrer K; Albers P; Nettersheim D Br J Cancer; 2020 Aug; 123(3):378-391. PubMed ID: 32418994 [TBL] [Abstract][Full Text] [Related]
5. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo. Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916 [TBL] [Abstract][Full Text] [Related]
6. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells. Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163 [TBL] [Abstract][Full Text] [Related]
7. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830 [TBL] [Abstract][Full Text] [Related]
8. A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. Goto Y; Koshizuka K; Ando T; Izumi H; Wu X; Sato K; Ishikawa T; Ford K; Feng X; Wang Z; Arang N; Allevato MM; Kishore A; Mali P; Gutkind JS Cancer Res Commun; 2024 Jul; 4(7):1850-1862. PubMed ID: 38954773 [TBL] [Abstract][Full Text] [Related]
9. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908 [TBL] [Abstract][Full Text] [Related]
11. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364 [TBL] [Abstract][Full Text] [Related]
12. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. Sumi NJ; Kuenzi BM; Knezevic CE; Remsing Rix LL; Rix U ACS Chem Biol; 2015 Dec; 10(12):2680-6. PubMed ID: 26390342 [TBL] [Abstract][Full Text] [Related]
13. Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity. Jin D; Tran N; Thomas N; Tran DD PLoS One; 2019; 14(10):e0223555. PubMed ID: 31600301 [TBL] [Abstract][Full Text] [Related]
14. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. Bonelli M; La Monica S; Fumarola C; Alfieri R Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925 [TBL] [Abstract][Full Text] [Related]
15. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721 [TBL] [Abstract][Full Text] [Related]
16. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634 [TBL] [Abstract][Full Text] [Related]
17. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484 [TBL] [Abstract][Full Text] [Related]
18. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512 [TBL] [Abstract][Full Text] [Related]
19. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy. Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667 [No Abstract] [Full Text] [Related]
20. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788 [No Abstract] [Full Text] [Related] [Next] [New Search]